Certain lesions, such as those attributed to +21, +8, +19, and ASXL1 and TP53 mutations, were enriched in myeloid crisis compared to those in lymphoid crisis, while others were enriched in lymphoid BC, which included CDKN2A/B and IKZF1 deletions, −7/del(7p), and −9/del(9p). The gene discussed is CDKN2A; the disease is breast cancer.